Richter Gedeon Nyrt.
Records under this name other than the patents Richter Gedeon Nyrt. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 42 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,476 | Process for the Preparation of 17-Hydroxy-6beta,7beta;15beta,16beta-Bismethylene-17alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid gamma-Lactone and Key Intermediates for this Process Held by another company In force · High confidence | In force | High confidence | |
| US 8,309,712 | Industrial Process for the Preparation of 17-Hydroxy-6BETA,7BETA;15BETA,16BETA-BISMETHYLENE-3-OXO-17ALPHA-PREGN-4-ENE-21-Carboxylic Acid Gamma-Lactone and Key Intermediates for This Process Held by another company In force · High confidence | In force | High confidence | |
| US 9,994,525 | H3 Antagonists Containing Phenoxypiperidine Core Structure Lapsed on the fee record Ended Jun 12, 2026 · High confidence | Lapsed on the fee record | Ended Jun 12, 2026 | High confidence |
| US 11,274,119 | Industrial process for the synthesis of nomegestrol-acetate Lapsed on the fee record Ended Mar 15, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 15, 2026 | USPTO record |
| US 11,091,436 | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters Lapsed on the fee record Ended Aug 17, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 17, 2025 | USPTO record |
| US 9,717,691 | Pharmaceutical containing a hormone combination having a contraceptive effect and an insulin sensitizer Lapsed on the fee record Ended Aug 1, 2025 · USPTO record | Lapsed on the fee record | Ended Aug 1, 2025 | USPTO record |
| US 9,683,010 | Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives Lapsed on the fee record Ended Jun 20, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | USPTO record |
| US 7,435,744 | Piperdine Derivatives as Nmda Receptor Antagonists Formerly held Term ended Term ended Nov 5, 2024 · High confidence | Term ended | Term ended Nov 5, 2024 | High confidence |
| US 9,458,207 | Methods for refolding G-CSF from inclusion bodies Lapsed on the fee record Ended Oct 4, 2024 · USPTO record | Lapsed on the fee record | Ended Oct 4, 2024 | USPTO record |
| US 9,416,164 | Method for the production of polypeptides Lapsed on the fee record Ended Aug 16, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 16, 2024 | USPTO record |